![Big takeaway from ASCO: 70 percent of women with early breast cancer don't benefit from adjuvant chemotherapy](https://cdn.cancerletter.com/media/2018/06/breast-cancer-web.jpg)
![Big takeaway from ASCO: 70 percent of women with early breast cancer don't benefit from adjuvant chemotherapy](https://cdn.cancerletter.com/media/2018/06/breast-cancer-web.jpg)
Cover Story
Free
An NCI-sponsored trial showed that up to 70 percent of women with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer would not benefit from chemotherapy.
In Brief
Funding Opportunities
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Lei Zheng named executive director of Mays Cancer Center
- Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence - NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready”
“All research now involves data science at some level.”